- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03825146
The Effects of AMPC in the Treatments of Refractory or Relapsed AML (AMPCAL)
A Phase I Single-arm, Open-label Prospective Study to Evaluate the Efficacy and Safety of Peripheral Blood Derived Autologous Multi-lineage Potential Cells (AMPC) in Relapsed/Refractory Acute Myeloid Leukemia (AMPCAL Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After inclusion and exclusion criteria has been determined and approved, written informed consent will be obtained from the candidate. All medical history relevant to the diagnosis of AML will be collected.
Screening period:
The screening period could extend from 0 to 7 days depending on the completion of screening laboratory results as below.
On day -5 (up to day -1), the patient will undergo a screening test for the following test items:
- BUN, creatinine, electrolyte, liver function test (LFT)
- Full blood count (FBC), including blood smear
- Hepatitis B/C
- Human T lymphocytic virus type I and II (HTLV-I/II)
- HIV1/2
- Syphilis serology
- Mycoplasma serology For Hepatitis B/C,HTLV-I/II, HIV1/2, Syphilis serology, and Mycoplasma serology, these tests obtained up to 3 months prior to day -5 can be allowed for using as screening result.
- Chest X-ray
- Bone marrow study including aspiration with wright's stain, biopsy, flow cytometry, and chromosome study (Any molecular testing for AML is optional.).
Bone marrow biopsy can be omitted if the prior study performed within 14 days before day-5 and the available materials (core biopsy and slides) and result can be obtained for pathological review. In this case, only bone marrow aspiration for Wright's stain, flow cytometry, and chromosome study will be performed.
Bone marrow biopsy will be repeated if the previous result has been performed more than 14 days prior to day -5 and/or FBC at day -5 reveals peripheral blast count higher than 10% of total white blood cells.
For chromosome study (cytogenetics), the previous result before the recent line of chemotherapy prior to enrollment can be used for the screening data.
On day 0, peripheral blood will then be collected, ranging from 250mL to 400mL depending on candidate fitness. The blood is collected into a sterile blood bag and sealed. Subsequent processes will be conducted in the blood bag within a closed-system to minimize contamination risks. FBC will be collected in order to determine the disease status. After that, the investigator will consider to prescribe blood transfusion for the candidate.
On day 0 to day 3, the collected blood will be sent to the laboratory for stem cell culture, and a sample of the collected blood will be sent to a third-party laboratory for contamination testing of the following parameters:
- Bacterial endotoxin
- Total viable aerobic count
- Total viable count
- Microbial growth
- Mycoplasma real-time PCR test
On day 4, the biotest results will be released and the safety profiles of the AMPC product must be completed and passed before the cultured stem cells may be released for treatment
On day 5, candidates will receive an infusion of the cultured stem cells. Prior to the infusion, FBC and blood chemistry (BUN, Cr, electrolyte, LFT) will be collected and the treating doctor will first conduct an allergy skin test to determine suitability for reinfusion. The cultured stem cells are then reinfused intravenously into the candidate in a process that could take up to 2 hours
The candidate participation will take place on day 0 to day 1 or 2 (if blood transfusion is required) and day 5 (period adjusted for blood transfusion if required) for peripheral blood collection and stem cell reinfusion respectively; with 12 month follow up after treatment;
- 3 days post-treatment follow-up: full blood count test and blood smear, BUN, Cr, electrolyte, LFT
- 10 days post-treatment follow-up: full blood count test and blood smear, BUN, Cr, electrolyte, LFT
- 1 month (+/-7 days) post-treatment follow-up: full blood count test and blood smear, BUN, Cr, electrolyte, LFT, bone marrow study
- 3 month (+/-7 days) post-treatment follow-up: full blood count test and blood smear, BUN, Cr, electrolyte, LFT, bone marrow study
- 6 month (+/-7 days) post-treatment follow-up: full blood count test with bone marrow study
- 12 month (+/-7 days) post-treatment follow-up: full blood count test with bone marrow study
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Supachai Ekwattanakit, Ph.D, M.D.
- Phone Number: +66-86393-3452
- Email: supachai.ekw@mahidol.ac.th
Study Locations
-
-
-
Samut Sakhon, Thailand, 74000
- Recruiting
- Panacee Hospital Rama 2
-
Contact:
- Supachai Ekwattanakit, Ph.D., M.D.
- Phone Number: +66-86393-3452
- Email: supachai.ekw@mahidol.ac.th
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be unequivocally diagnosed with AML according to WHO classification with accompanying bone marrow biopsy and blood panel results
- Must have refractory AML, defined as disease unresponsive to initial treatment; or relapsed AML that re-occured after treatment with conventional high dose chemotherapy
- Candidates who have no available match-sibling donor for bone marrow transplantation (BMT) or are not suitable for BMT due to any reason.
- Must have had prior treatment with chemotherapy at least 30 days prior to day 0 of this study and have recovered from treatment-related toxicity of chemotherapeutic agents with the exception of persistent diseases
- Age 20 to 60 years old
Exclusion Criteria:
- Candidates who received any investigational therapies 4 weeks prior to treatment with this protocol
- Candidates who received radiotherapy within 4 weeks prior to the treatment of this protocol
- Candidates who have not recovered from any AE caused by radiotherapy or any agents received 4 weeks earlier
- Candidates who have had a prior allogeneic stem cell transplant
- Known case of extramedullary myeloid tumor (myeloid sarcoma)
- Pregnant or breastfeeding women
- Hydroxyurea has been prescribed within 10 days prior to day-5
Candidates have any abnormal screening laboratory results as below;
- Hemoglobin < 9 g/dL
- Total white blood cells count > 30,000/microL (without ongoing G-CSF therapy)
- Platelet count < 75,000/microL
- Creatinine clearance < 30 mL/min/1.73 m2 (by Cockcroft and Gault formula)
- ALT > 5x upper normal limit
- Bone marrow study at screening period show blast > 40% of total nucleated cells or severe hypocellularity (defined as < 25% of normal cellularity for corresponding age) with presence of cluster of blasts
- Candidates have active heart disease including recent or chronic heart failure, unstable angina, recent acute myocardial infarction, or significant arrhythmia within 6 months of recruitment.
- Candidates have concurrent malignancies unless the candidates has been free of the disease for at least 5 years.
- Candidates positive for HIV1/2, hepatitis B/C, HTLVI/II, and Syphilis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment Arm (AMPC)
AMPC will be intravenously infused.
|
Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion. An estimated average of 1 x 10^8 (0.5 to 5.0 x 10^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR) of AMPC in refractory/relapsed AML at 12 months
Time Frame: 12 months
|
Overall response rate (ORR) is defined as whether the patient achieves complete remission (CR) or complete remission with incomplete blood count recovery (CRi) CR Requirements:
CRi Requirements:
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety profile and treatment-related adverse events (AE) upto 12-month follow up period
Time Frame: 12 months
|
AE is defined as any unintended or undesirable experience that occur during the course of the clinical investigation regardless of whether they are considered to be drug-related.
|
12 months
|
ORR of AMPC in refractory/relapsed AML at 3 and 6 months
Time Frame: 3 and 6 months
|
3 and 6 months
|
|
Overall survival (OS) rate at 12 months
Time Frame: 12 months
|
12 months
|
|
Time-to-next treatment (TTNT), defined as the time from the start of AMPC therapy to the start date of a subsequent line of therapy.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Supachai Ekwattanakit, Ph.D, M.D., Panacee Hospital Rama 2
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SOP-PNC-REC-01/01-061
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukaemia Recurrent
-
University of LeipzigCompletedAcute Myeloid LeukaemiaGermany
-
University of SydneyMelbourne Health; Royal Brisbane and Women's HospitalUnknown
-
Great Ormond Street Hospital for Children NHS Foundation...Wellcome TrustRecruitingRelapsed Acute Myeloid LeukaemiaUnited Kingdom
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedAcute Myeloid LeukaemiaFrance, United States, Australia
-
AstraZenecaCompletedAcute Myeloid LeukaemiaUnited Kingdom
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyActive, not recruitingAcute Myeloid LeukaemiaUnited States, Australia, France, Spain
-
AstraZenecaTerminatedAcute Myeloid LeukaemiaUnited States, Australia
-
Cellectis S.A.WithdrawnAcute Myeloid Leukaemia
-
Hospices Civils de LyonCompleted
-
medac GmbHCompleted
Clinical Trials on Autologous Multi-lineage Potential Cells (AMPC)
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingDiffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin LymphomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)Not yet recruitingTriple Negative Breast CancerUnited States